NCT03152318 - A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 18, 2017

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions

Malignant Glioma of BrainAstrocytomaMalignant AstrocytomaOligodendrogliomaAnaplastic Oligodendroglioma of Brain (Diagnosis)Mixed Oligo-AstrocytomaEpendymomaGangliogliomaPylocytic/Pylomyxoid AstrocytomaBrain TumorGliomaBrain CancerGlioblastomaGlioblastoma Multiforme

Interventions

DRUG

rQNestin

rQNestin is an oncolytic viral vector. It is administered via intratumoral injection during biopsy surgery.

DRUG

Cyclophosphamide

Cyclophosphamide is an immunomodulating agent. It is administered intravenously in a single dose 2 days (+/- 6 hrs) before surgery.

PROCEDURE

Stereotactic biopsy

In both arms, subjects will undergo standard of care stereotactic biopsy in the intraoperative MRI operating room. The stereotactic needle will be placed stereotactically into the tumor bed using intraoperative MRI guidance to collect the biopsy, and again to administer the rQNestin oncolytic virus.

Trial Locations (5)

10065

NOT_YET_RECRUITING

Memorial Sloan Kettering Cancer Center, New York

21287

NOT_YET_RECRUITING

Johns Hopkins University Medical Center, Baltimore

77030

NOT_YET_RECRUITING

MD Anderson Cancer Center, Houston

02115

RECRUITING

Dana Farber Cancer Institute, Boston

02215

RECRUITING

Brigham and Women's Hospital, Boston